What are the BMS–BioNTech BNT327 deal terms?
On June 2, 2025, Bristol Myers Squibb and BioNTech announced a BNT327 partnership with $1.5 billion upfront, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in additional milestones. These components sum to a potential $11.1 billion; BNT327 targets PD-L1 and VEGF-A, so it should be distinguished from PD-1×VEGF candidates.
| Measure | Reported result | Basis |
|---|---|---|
| Upfront payment | $1.5 billion | At the partnership outset |
| Non-contingent payments | $2 billion | Anniversary payments through 2028 |
| Potential milestones | Up to $7.6 billion | Additional conditional payments |
| Potential total | Up to $11.1 billion | Calculated: upfront plus anniversary payments plus milestones |
Ivonescimab after the FDA letter
On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026